336 related articles for article (PubMed ID: 33725358)
1. Proteomics for Target Identification in Psychiatric and Neurodegenerative Disorders.
Antunes ASLM; de Almeida V; Crunfli F; Carregari VC; Martins-de-Souza D
Adv Exp Med Biol; 2021; 1286():251-264. PubMed ID: 33725358
[TBL] [Abstract][Full Text] [Related]
2. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders.
Abdi F; Quinn JF; Jankovic J; McIntosh M; Leverenz JB; Peskind E; Nixon R; Nutt J; Chung K; Zabetian C; Samii A; Lin M; Hattan S; Pan C; Wang Y; Jin J; Zhu D; Li GJ; Liu Y; Waichunas D; Montine TJ; Zhang J
J Alzheimers Dis; 2006 Aug; 9(3):293-348. PubMed ID: 16914840
[TBL] [Abstract][Full Text] [Related]
3. The use of MALDI-MSI in the investigation of psychiatric and neurodegenerative disorders: A review.
Schubert KO; Weiland F; Baune BT; Hoffmann P
Proteomics; 2016 Jun; 16(11-12):1747-58. PubMed ID: 27303929
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers in Neurodegenerative Diseases.
Jeromin A; Bowser R
Adv Neurobiol; 2017; 15():491-528. PubMed ID: 28674995
[TBL] [Abstract][Full Text] [Related]
5. [CSF biomarkers: proteomics investigations and clinical applications in neurodegenerative disorders].
Gabelle A; Roche S; Lehmann S
Rev Neurol (Paris); 2009 Mar; 165(3):213-22. PubMed ID: 18808768
[TBL] [Abstract][Full Text] [Related]
6. Cerebrospinal fluid protein biomarkers in Parkinson's disease.
Faizan M; Sachan N; Verma O; Sarkar A; Rawat N; Pratap Singh M
Clin Chim Acta; 2024 Mar; 556():117848. PubMed ID: 38417781
[TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid biomarkers in Alzheimer's and Parkinson's diseases-From pathophysiology to clinical practice.
Blennow K; Biscetti L; Eusebi P; Parnetti L
Mov Disord; 2016 Jun; 31(6):836-47. PubMed ID: 27145480
[TBL] [Abstract][Full Text] [Related]
8. Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.
Mayo S; Benito-León J; Peña-Bautista C; Baquero M; Cháfer-Pericás C
Curr Neuropharmacol; 2021; 19(8):1273-1303. PubMed ID: 33357195
[TBL] [Abstract][Full Text] [Related]
9. Omics Data and Their Integrative Analysis to Support Stratified Medicine in Neurodegenerative Diseases.
La Cognata V; Morello G; Cavallaro S
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34062930
[TBL] [Abstract][Full Text] [Related]
10. Proteomics in animal models of Alzheimer's and Parkinson's diseases.
Sowell RA; Owen JB; Butterfield DA
Ageing Res Rev; 2009 Jan; 8(1):1-17. PubMed ID: 18703168
[TBL] [Abstract][Full Text] [Related]
11. Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases.
Htike TT; Mishra S; Kumar S; Padmanabhan P; Gulyás B
Mol Neurobiol; 2019 Mar; 56(3):2256-2277. PubMed ID: 30008073
[TBL] [Abstract][Full Text] [Related]
12. Dissecting Alzheimer's Disease Molecular Substrates by Proteomics and Discovery of Novel Post-translational Modifications.
Deolankar SC; Patil AH; Koyangana SG; Subbannayya Y; Prasad TSK; Modi PK
OMICS; 2019 Jul; 23(7):350-361. PubMed ID: 31225774
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
Parnetti L; Eusebi P; Lleó A
Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974
[TBL] [Abstract][Full Text] [Related]
14. Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease.
Robinson RA; Amin B; Guest PC
Adv Exp Med Biol; 2017; 974():21-48. PubMed ID: 28353223
[TBL] [Abstract][Full Text] [Related]
15. Identifying the Association Between Alzheimer's Disease and Parkinson's Disease Using Genome-Wide Association Studies and Protein-Protein Interaction Network.
Liu G; Bao X; Jiang Y; Liao M; Jiang Q; Feng R; Zhang L; Ma G; Chen Z; Wang G; Wang R; Zhao B; Li K
Mol Neurobiol; 2015 Dec; 52(3):1629-1636. PubMed ID: 25370933
[TBL] [Abstract][Full Text] [Related]
16. Morphometric and Nanomechanical Screening of Peripheral Blood Cells with Atomic Force Microscopy for Label-Free Assessment of Alzheimer's Disease, Parkinson's Disease, and Amyotrophic Lateral Sclerosis.
Taneva SG; Todinova S; Andreeva T
Int J Mol Sci; 2023 Sep; 24(18):. PubMed ID: 37762599
[TBL] [Abstract][Full Text] [Related]
17. Psychotropic Drug Development Strategies that Target Neuropsychiatric Etiologies in Alzheimer's and Parkinson's Diseases.
Van der Schyf CJ
Drug Dev Res; 2016 Dec; 77(8):458-468. PubMed ID: 27813127
[TBL] [Abstract][Full Text] [Related]
18. Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?
Moya-Alvarado G; Gershoni-Emek N; Perlson E; Bronfman FC
Mol Cell Proteomics; 2016 Feb; 15(2):409-25. PubMed ID: 26657538
[TBL] [Abstract][Full Text] [Related]
19. The Immune System and Neuroinflammation as Potential Sources of Blood-Based Biomarkers for Alzheimer's Disease, Parkinson's Disease, and Huntington's Disease.
Clark LF; Kodadek T
ACS Chem Neurosci; 2016 May; 7(5):520-7. PubMed ID: 27046268
[TBL] [Abstract][Full Text] [Related]
20. Omics-based biomarkers discovery for Alzheimer's disease.
Aerqin Q; Wang ZT; Wu KM; He XY; Dong Q; Yu JT
Cell Mol Life Sci; 2022 Nov; 79(12):585. PubMed ID: 36348101
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
